Can procalcitonin levels indicate the need for adjunctive therapies in sepsis?

After decades of extensive experimental and clinical research, septic shock and the related multiple organ dysfunction still remain the leading cause of mortality in intensive care units (ICUs) worldwide. Defining sepsis is a difficult task, but what is even more challenging is differentiating infec...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Becze Zsolt
Molnár Zsolt
Fazakas János
Dokumentumtípus: Cikk
Megjelent: 2015
Sorozat:INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 46 No. Suppl. 1
doi:10.1016/j.ijantimicag.2015.11.002

mtmt:2983110
Online Access:http://publicatio.bibl.u-szeged.hu/11622
LEADER 02328nab a2200229 i 4500
001 publ11622
005 20200117153923.0
008 170622s2015 hu o 0|| zxx d
022 |a 0924-8579 
024 7 |a 10.1016/j.ijantimicag.2015.11.002  |2 doi 
024 7 |a 2983110  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Becze Zsolt 
245 1 0 |a Can procalcitonin levels indicate the need for adjunctive therapies in sepsis?  |h [elektronikus dokumentum] /  |c  Becze Zsolt 
260 |c 2015 
300 |a S13-S18 
490 0 |a INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  |v 46 No. Suppl. 1 
520 3 |a After decades of extensive experimental and clinical research, septic shock and the related multiple organ dysfunction still remain the leading cause of mortality in intensive care units (ICUs) worldwide. Defining sepsis is a difficult task, but what is even more challenging is differentiating infection-induced from non-infection-induced systemic inflammatory response-related multiple organ dysfunction. As conventional signs of infection are often unreliable in intensive care, biomarkers are used, of which one of the most frequently investigated is procalcitonin. Early stabilisation of vital functions via adequate supportive therapy and antibiotic treatment has resulted in substantial improvements in outcome over the last decades. However, there are certain patients who may need extra help, hence modulation of the immune system and the host's response may also be an important therapeutic approach in these situations. Polyclonal intravenous immunoglobulins have been used in critical care for decades. A relatively new potential approach could be attenuation of the overwhelming cytokine storm by specific cytokine adsorbents. Both interventions have been applied in daily practice on a large scale, with firm pathophysiological rationale but weak evidence supported by clinical trials. The purpose of this review is to give an overview on the pathophysiology of sepsis as well as the role and interpretation of biomarkers and their potential use in assisting adjunctive therapies in sepsis in the future. 
700 0 1 |a Molnár Zsolt  |e aut 
700 0 1 |a Fazakas János  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/11622/1/1_s2.0_S0924857915003659_main_u.pdf  |z Dokumentum-elérés